AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22910901 — intervention group
Group type: EXPERIMENTAL
Intervention: Number-cued saccades with increased response alternatives (from two to six)
Number of subjects: 0
Study 22910901 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccades with increased response alternatives (from two to six)
Number of subjects: 0
Study 20946621 — intervention group
Group type: EXPERIMENTAL
Intervention: Active physiotherapy treatment (manual therapy and exercise plus education and advice)
Number of subjects: 128
Study 20946621 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (sham ultrasound and non‐therapeutic gel)
Number of subjects: 128
Study 17288625 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-tailored advice and brief dietary counselling
Number of subjects: 486
Study 17288625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 486
Study 16128939 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 150
Study 16128939 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus Meperidine
Number of subjects: 150
Study 12154207 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (100 mg initially, then 20 mg/day)
Number of subjects: 1817
Study 12154207 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (15-20 mg/day)
Number of subjects: 1817
Study 12154207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (2 g/day)
Number of subjects: 1817
Study 12154207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1817
Study 10591720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 199
Study 10591720 — intervention group
Group type: COMPARATOR
Intervention: Hospital ward
Number of subjects: 199
Study 7767451 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization in an ankle brace (1-2 weeks after surgery)
Number of subjects: 30
Study 7767451 — intervention group
Group type: COMPARATOR
Intervention: Postoperative immobilization in a plaster cast for 6 weeks
Number of subjects: 30
Study 7767451 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization in an ankle brace
Number of subjects: 30
Study 2394119 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 44
Study 2394119 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 44
Study 7018680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vinblastine-CCNU
Number of subjects: 133
Study 7018680 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent triazinate
Number of subjects: 133
Study 7018680 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent dactinomycin
Number of subjects: 133
Study 30478814 — intervention group
Group type: EXPERIMENTAL
Intervention: DSCT flash caudo‐cranial acquisition (P2)
Number of subjects: 60
Study 28508568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure sensing system with real-time visual feedback
Number of subjects: 30
Study 28508568 — intervention group
Group type: COMPARATOR
Intervention: Standard mask fitting procedures
Number of subjects: 30
Study 25980570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary-specific Quality-of-Life Scale (PQLS)
Number of subjects: 389
Study 25980570 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 389
Study 24399187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing formulation only (Group 1)
Number of subjects: 60
Study 24399187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing solution and moisturizing solution (Group 2)
Number of subjects: 60
Study 24399187 — intervention group
Group type: COMPARATOR
Intervention: Cleansing formulation and moisturizing formulation (Group 3)
Number of subjects: 60
Study 21415069 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin activity (PRA) in the highest fifth of the PRA distribution
Number of subjects: 2913
Study 21415069 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PRA measurement
Number of subjects: 2913
Study 19699443 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher densities of employees in neighborhood destinations for youth
Number of subjects: 152
Study 19699443 — intervention group
Group type: COMPARATOR
Intervention: Lower densities of employees in neighborhood destinations for youth
Number of subjects: 152
Study 18991158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (n=7)
Number of subjects: 14
Study 18991158 — intervention group
Group type: COMPARATOR
Intervention: Waiting list Control Group (n=7)
Number of subjects: 14
Study 18991158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups at 3-month follow-up
Number of subjects: 14
Study 15804684 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 21‐mg nicotine patch
Number of subjects: 1309
Study 15804684 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 2‐mg or 4-mg nicotine lozenge
Number of subjects: 1309
Study 15804684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both patch and lozenge)
Number of subjects: 1309
Study 12153829 — intervention group
Group type: EXPERIMENTAL
Intervention: WS 5570 (300 mg t.i.d.)
Number of subjects: 375
Study 12153829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 10340155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant odor
Number of subjects: 0
Study 10340155 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant odor
Number of subjects: 0
Study 10340155 — intervention group
Group type: COMPARATOR
Intervention: Control odor (water)
Number of subjects: 0
Study 10340155 — intervention group
Group type: EXPERIMENTAL
Intervention: Odors eliciting negative-affect-related expressions
Number of subjects: 0
Study 10340155 — intervention group
Group type: EXPERIMENTAL
Intervention: Odors that did not elicit negative-affect-related expressions
Number of subjects: 0
Study 7562226 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulator (TENS)
Number of subjects: 71
Study 7562226 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 71
Study 7562226 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 2085991 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT) 3 g single dose
Number of subjects: 291
Study 2085991 — intervention group
Group type: COMPARATOR
Intervention: Pipemidic acid (PA) 400 mg b.i.d. for seven days
Number of subjects: 291
Study 2085991 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT)
Number of subjects: 291
Study 2085991 — intervention group
Group type: COMPARATOR
Intervention: Pipemidic acid (PA)
Number of subjects: 291
Study 343660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.4 mg t.i.d.)
Number of subjects: 28
Study 343660 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (0.15 mg t.i.d.)
Number of subjects: 28
Study 29807811 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated nasal packing
Number of subjects: 80
Study 29807811 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-impregnated nasal packing
Number of subjects: 80
Study 29807811 — intervention group
Group type: COMPARATOR
Intervention: Saline solution-impregnated nasal packing
Number of subjects: 80
Study 28333952 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 (3.5mg daily for 9 months)
Number of subjects: 170
Study 28333952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 24444038 — intervention group
Group type: COMPARATOR
Intervention: T1DM-P (HbA1c ≥ 9.0%)
Number of subjects: 24
Study 24444038 — intervention group
Group type: COMPARATOR
Intervention: T1DM-G (HbA1c ≤ 7.5%)
Number of subjects: 24
Study 24444038 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 24444038 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (T1DM-G, T1DM-P, controls)
Number of subjects: 24
Study 23932793 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy
Number of subjects: 0
Study 23932793 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 0
Study 23932793 — intervention group
Group type: COMPARATOR
Intervention: Pill-placebo
Number of subjects: 0
Study 23932793 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 21808844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam
Number of subjects: 90
Study 21808844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg midazolam
Number of subjects: 90
Study 21808844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1 ml/kg orange flavored juice)
Number of subjects: 90
Study 19095163 — intervention group
Group type: EXPERIMENTAL
Intervention: FC-Interactive Voice Response (IVR) counseling
Number of subjects: 220
Study 19095163 — intervention group
Group type: EXPERIMENTAL
Intervention: FC-Interactive Voice Response (IVR) counseling (with at least six completed calls)
Number of subjects: 220
Study 19095163 — intervention group
Group type: COMPARATOR
Intervention: FC-workbook
Number of subjects: 220
Study 19095163 — intervention group
Group type: COMPARATOR
Intervention: FC-group
Number of subjects: 220
Study 19095163 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 220
Study 16525095 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 587
Study 16525095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 587
Study 12406891 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+‐selected PBSCs
Number of subjects: 32
Study 12406891 — intervention group
Group type: COMPARATOR
Intervention: Unselected PBSCs
Number of subjects: 32
Study 10759039 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session (SS) treatment
Number of subjects: 105
Study 10759039 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-as-needed (TAN)
Number of subjects: 105
Study 8832303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid with glycine (test formulation)
Number of subjects: 12
Study 8832303 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid without glycine (reference formulation)
Number of subjects: 12
Study 1486964 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (10(‐2) M)
Number of subjects: 10
Study 1486964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6428120 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + glibenclamide
Number of subjects: 13
Study 6428120 — intervention group
Group type: COMPARATOR
Intervention: Insulin + placebo
Number of subjects: 13
Study 30902539 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching backward
Number of subjects: 41
Study 30902539 — intervention group
Group type: COMPARATOR
Intervention: Reaching forward
Number of subjects: 41
Study 30029290 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared indocyanine green (ICG) fluorescence
Number of subjects: 0
Study 30029290 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment under white light
Number of subjects: 0
Study 27234693 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 1369
Study 27234693 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1369
Study 24491201 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, exposure-based intervention
Number of subjects: 40
Study 24491201 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 40
Study 21833487 — intervention group
Group type: EXPERIMENTAL
Intervention: Footbath (30 min immersion in water at 41 to 43°C)
Number of subjects: 32
Study 21833487 — intervention group
Group type: COMPARATOR
Intervention: Control (no footbath)
Number of subjects: 32
Study 20920045 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS) injected once or twice daily
Number of subjects: 471
Study 20920045 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine injected once daily
Number of subjects: 471
Study 20920045 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 471
Study 20920045 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 471
Study 18389675 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 80
Study 18389675 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil
Number of subjects: 80
Study 18389675 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 80
Study 18389675 — intervention group
Group type: COMPARATOR
Intervention: Azadirachta indica (Neem) extract
Number of subjects: 80
Study 15804248 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral creatine (Cr) monohydrate at a dosage of 150 mg/kg body weight/day
Number of subjects: 15
Study 15804248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12519334 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading of ITI implants (6 weeks healing)
Number of subjects: 24
Study 12519334 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading of ITI implants (12 weeks healing)
Number of subjects: 24
Study 10233426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 0
Study 10233426 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 8598501 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional posted foot orthoses
Number of subjects: 0
Study 8598501 — intervention group
Group type: COMPARATOR
Intervention: Placebo orthoses
Number of subjects: 0
Study 1844168 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cow's milk formula (LPM)
Number of subjects: 2097
Study 7201816 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortolone monohydrate (Syracort) applied at 4-13-day intervals
Number of subjects: 1573
Study 7201816 — intervention group
Group type: EXPERIMENTAL
Intervention: Syracerin (steroid-free partner drug) applied at 4-13-day intervals
Number of subjects: 1573
Study 7201816 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval application of topical corticoids
Number of subjects: 1573
Study 30829316 — intervention group
Group type: EXPERIMENTAL
Intervention: ZEB1 siRNA
Number of subjects: 2
Study 30829316 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 30829316 — intervention group
Group type: COMPARATOR
Intervention: Scramble group
Number of subjects: 2
Study 30548426 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO; 145 g; n=9)
Number of subjects: 17
Study 26719947 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate prescription strategy
Number of subjects: 405
Study 26719947 — intervention group
Group type: COMPARATOR
Intervention: No prescription strategy
Number of subjects: 405
Study 26719947 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed prescription collection strategy
Number of subjects: 405
Study 26719947 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed patient-led prescription strategy
Number of subjects: 405
Study 26719947 — intervention group
Group type: EXPERIMENTAL
Intervention: All delayed strategies (patient-led and collection)
Number of subjects: 405
Study 24557661 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram (ESC) + bupropion (BUP)
Number of subjects: 51
Study 24557661 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram (ESC)
Number of subjects: 51
Study 24557661 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion (BUP)
Number of subjects: 51
Study 24557661 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP
Number of subjects: 51
Study 24557661 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline alpha2 power
Number of subjects: 51
Study 24557661 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha2 asymmetry
Number of subjects: 51
Study 21813573 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐min lower‐limb resistance exercises with vascular measurements in the calf (RELL)
Number of subjects: 10
Study 21813573 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐min lower‐limb resistance exercises with vascular measurements in the forearm (REUL)
Number of subjects: 10
Study 21813573 — intervention group
Group type: COMPARATOR
Intervention: 25‐min rest (control)
Number of subjects: 10
Study 20670733 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 200 microg/day
Number of subjects: 140
Study 20670733 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 800 microg/day
Number of subjects: 140
Study 20670733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 17513173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg/day until disease progression
Number of subjects: 400
Study 17513173 — intervention group
Group type: COMPARATOR
Intervention: Standard gemcitabine infusion
Number of subjects: 400
Study 17513173 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI gemcitabine 1200 mg/m(2) in a 120-min infusion
Number of subjects: 400
Study 17513173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 400
Study 17027423 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal interventions
Number of subjects: 0
Study 17027423 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 12175131 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis (specific details not provided)
Number of subjects: 30
Study 12175131 — intervention group
Group type: COMPARATOR
Intervention: Control groups (Group A, Group B, Group C)
Number of subjects: 30
Study 10452209 — intervention group
Group type: EXPERIMENTAL
Intervention: Three telephone calls and oral and written self-care measures for specific side effects
Number of subjects: 48
Study 10452209 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study 10452209 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ESCA scores before chemotherapy
Number of subjects: 48
Study 10452209 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call and written self-care measures after the second, third, and fourth chemotherapy treatments
Number of subjects: 48
Study 7598066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (20 mmol/24 h)
Number of subjects: 68
Study 2180341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin (0.14 mg/kg)
Number of subjects: 0
Study 288173 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 48
Study 288173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 48
Study 288173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31634532 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 196
Study 31634532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 30994790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy accompanied by 1% gentian violet application (group 2)
Number of subjects: 59
Study 30994790 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone (group 1)
Number of subjects: 59
Study 30994790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 29085387 — intervention group
Group type: EXPERIMENTAL
Intervention: TCMS plus PEDT combination therapy
Number of subjects: 90
Study 29085387 — intervention group
Group type: COMPARATOR
Intervention: TCMS monotherapy
Number of subjects: 90
Study 29085387 — intervention group
Group type: COMPARATOR
Intervention: PEDT monotherapy
Number of subjects: 90
Study 25327838 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide Attempt (SA)
Number of subjects: 181
Study 25327838 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal Ideation (SI)
Number of subjects: 181
Study 25327838 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SA and SI groups
Number of subjects: 181
Study 25327838 — intervention group
Group type: COMPARATOR
Intervention: Parent and youth self-reports
Number of subjects: 181
Study 25327838 — intervention group
Group type: COMPARATOR
Intervention: Independent judges and youth reports
Number of subjects: 181
Study 23372095 — intervention group
Group type: COMPARATOR
Intervention: Oncology nurse navigator program
Number of subjects: 0
Study 21792758 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with combined preoperative intraarterial infusion and intravenous chemotherapy before gastrectomy and D2 lymphadenectomy
Number of subjects: 139
Study 21792758 — intervention group
Group type: COMPARATOR
Intervention: Gastrectomy and D2 lymphadenectomy alone
Number of subjects: 139
Study 19472556 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Paste (8% arginine and calcium carbonate)
Number of subjects: 68
Study 19472556 — intervention group
Group type: COMPARATOR
Intervention: Control Paste (Nupro pumice prophylaxis paste)
Number of subjects: 68
Study 17257877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal vaccine candidate (50 microg HBsAg and 50 microg HBcAg)
Number of subjects: 19
Study 17257877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% physiologic saline solution)
Number of subjects: 19
Study 14665895 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg once daily)
Number of subjects: 64
Study 14665895 — intervention group
Group type: COMPARATOR
Intervention: Saw palmetto (325 mg daily)
Number of subjects: 64
Study 11695935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg, twice daily for 12 months)
Number of subjects: 277
Study 11695935 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (200 microg, twice daily for 12 months)
Number of subjects: 277
Study 11695935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 277
Study 11695935 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate
Number of subjects: 277
Study 11695935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and Beclomethasone dipropionate
Number of subjects: 277
Study 10799790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively intact patients
Number of subjects: 97